Isomorphic Labs launched the Drug Design Engine (IsoDDE), surpassing AlphaFold 3 in predictive accuracy. IsoDDE improves small molecule binding-affinity predictions and identifies binding pockets using only amino acid sequences, enhancing drug discovery capabilities.
Isomorphic Labs has introduced the IsoDDE, a unified drug-design system that progresses beyond AlphaFold 3 in predictive performance. This new engine addresses existing challenges in drug discovery by enhancing accurate biomolecular structure and interaction modeling.
IsoDDE demonstrates over double the accuracy of AlphaFold 3 on a generalization benchmark for protein-ligand structure predictions. It also predicts small molecule binding affinities more accurately than traditional physics-based methods, achieving these results faster and at a lower cost.
The engine can identify novel binding pockets on target proteins using only the amino acid sequence of the protein. This capability is essential for exploratory drug design, particularly as it significantly enhances the understanding of molecular interactions.
With its predictive fidelity, IsoDDE is positioned to advance AI drug design, facilitating exploration of previously uncharted biochemical terrains. Such capabilities are vital for developing therapies that address complex human diseases effectively.
The launch of IsoDDE signifies a significant move forward in the field of AI-driven drug discovery, suggesting that AI models are increasingly able to generalize and tackle real-world applications in pharmaceutical development.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
Isomorphic Labs launched the Drug Design Engine (IsoDDE), surpassing AlphaFold 3 in predictive accuracy. IsoDDE improves small molecule binding-affinity predictions and identifies binding pockets using only amino acid sequences, enhancing drug discovery capabilities.